JP6580030B2 - カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途 - Google Patents

カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途 Download PDF

Info

Publication number
JP6580030B2
JP6580030B2 JP2016504038A JP2016504038A JP6580030B2 JP 6580030 B2 JP6580030 B2 JP 6580030B2 JP 2016504038 A JP2016504038 A JP 2016504038A JP 2016504038 A JP2016504038 A JP 2016504038A JP 6580030 B2 JP6580030 B2 JP 6580030B2
Authority
JP
Japan
Prior art keywords
group
hsp90 inhibitor
general formula
compound
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016504038A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2015125640A1 (ja
Inventor
麻奈美 岡▲崎▼
麻奈美 岡▲崎▼
丸山　佐起子
佐起子 丸山
亮 増田
亮 増田
啓一朗 山本
啓一朗 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of JPWO2015125640A1 publication Critical patent/JPWO2015125640A1/ja
Application granted granted Critical
Publication of JP6580030B2 publication Critical patent/JP6580030B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
JP2016504038A 2014-02-19 2015-02-09 カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途 Expired - Fee Related JP6580030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014029048 2014-02-19
JP2014029048 2014-02-19
PCT/JP2015/053479 WO2015125640A1 (fr) 2014-02-19 2015-02-09 Composé polymère auquel sont liés un dérivé de camptothécine et un inhibiteur de hsp90, et son utilisation

Publications (2)

Publication Number Publication Date
JPWO2015125640A1 JPWO2015125640A1 (ja) 2017-03-30
JP6580030B2 true JP6580030B2 (ja) 2019-09-25

Family

ID=53878146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016504038A Expired - Fee Related JP6580030B2 (ja) 2014-02-19 2015-02-09 カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途

Country Status (3)

Country Link
JP (1) JP6580030B2 (fr)
TW (1) TW201613652A (fr)
WO (1) WO2015125640A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017226131A1 (en) * 2016-03-01 2018-10-04 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation containing camptothecin-based polymeric derivative
WO2018025657A1 (fr) * 2016-07-30 2018-02-08 日本化薬株式会社 Nouveaux dérivés polymères, et nouvelle sonde d'imagerie dérivée de polymères utilisant lesdits nouveaux dérivés polymères

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1580216E (pt) * 2002-10-31 2014-07-31 Nippon Kayaku Kk Derivados de elevado peso molecular de camptotecinas
JP5548364B2 (ja) * 2006-10-03 2014-07-16 日本化薬株式会社 レゾルシノール誘導体の高分子結合体
JP2010519305A (ja) * 2007-02-26 2010-06-03 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 併用薬物送達のためのポリマー性ミセル
JP2014532712A (ja) * 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
JP6262201B2 (ja) * 2012-04-12 2018-01-17 日東電工株式会社 コポリマー結合体
JP6223995B2 (ja) * 2012-11-08 2017-11-01 日本化薬株式会社 カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途

Also Published As

Publication number Publication date
JPWO2015125640A1 (ja) 2017-03-30
TW201613652A (en) 2016-04-16
WO2015125640A1 (fr) 2015-08-27

Similar Documents

Publication Publication Date Title
JP2022166327A (ja) 癌の治療法
US11975002B2 (en) Preparation and composition for treatment of malignant tumors
TW201302850A (zh) 新穎之嵌段共聚物、微胞調製物及將其作為有效成分之抗癌劑
US20080207516A1 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US11883404B2 (en) Preparation and composition for treatment of malignant tumors
TWI598108B (zh) Polymer compounds with camptothecins and anticancer effect enhancers and their uses
CN103442563A (zh) 癌症治疗
JP6229865B2 (ja) エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物
JP6461088B2 (ja) 高分子化カンプトテシン誘導体及び高分子化ｈｓｐ９０阻害剤誘導体を含む医薬組成物
KR20170120568A (ko) 생리활성물질결합 블록 공중합체
JP6580030B2 (ja) カンプトテシン誘導体とｈｓｐ９０阻害剤の結合した高分子化合物及びその用途
WO2014084378A1 (fr) Médicament anticancéreux comprenant un peptide contenant la séquence rgd cyclique
JP2017193591A (ja) 腫瘍細胞選択的抗がん剤
JP5843086B2 (ja) 治療活性物質の作用を増強するための高分子化環状ニトロキシドラジカル化合物の使用
JP7223502B6 (ja) 医薬組成物
JP7267609B2 (ja) 抗がん剤
US20130259944A1 (en) Methods and compositions for treating cancer with platinum particles
JP2022552841A (ja) ポリマー薬物送達コンジュゲートならびにそれを作製および使用する方法
TW202302151A (zh) 醫藥聚合物結合物
JP2022546415A (ja) 治療薬の核酸媒介性送達
AU2017226131A1 (en) Pharmaceutical preparation containing camptothecin-based polymeric derivative
KR20070018117A (ko) 17-ａａｇ를 함유하는 약제학적 용제

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190827

R150 Certificate of patent or registration of utility model

Ref document number: 6580030

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees